Bio-Rad Laboratories (NYSE:BIO) Rating Increased to Moderate Buy at Royal Bank Of Canada

Posted by Brian Himes on May 16th, 2026

Royal Bank Of Canada upgraded shares of Bio-Rad Laboratories (NYSE:BIO – Free Report) to a moderate buy rating in a report issued on Thursday,Zacks.com reports.

Other equities analysts have also issued reports about the company. Wall Street Zen lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Citigroup lowered Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and cut their target price for the company from $375.00 to $300.00 in a research report on Tuesday, April 7th. Wells Fargo & Company cut their target price on Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating on the stock in a research report on Friday, May 1st. Finally, Weiss Ratings lowered Bio-Rad Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, May 6th. One analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $303.33.

View Our Latest Analysis on Bio-Rad Laboratories

Bio-Rad Laboratories Stock Performance

Shares of BIO opened at $247.66 on Thursday. The business’s 50 day moving average is $273.25 and its two-hundred day moving average is $293.61. Bio-Rad Laboratories has a 52-week low of $211.43 and a 52-week high of $343.12. The firm has a market cap of $6.63 billion, a price-to-earnings ratio of 40.80 and a beta of 1.06. The company has a quick ratio of 2.37, a current ratio of 3.21 and a debt-to-equity ratio of 0.12.

Bio-Rad Laboratories (NYSE:BIO – Get Free Report) last announced its earnings results on Thursday, April 30th. The medical research company reported $1.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.97 by ($0.08). Bio-Rad Laboratories had a net margin of 6.52% and a return on equity of 3.56%. The business had revenue of $592.10 million during the quarter, compared to analyst estimates of $589.91 million. During the same period in the previous year, the company earned $2.54 earnings per share. The business’s revenue for the quarter was up 1.1% on a year-over-year basis. Analysts forecast that Bio-Rad Laboratories will post 10.32 EPS for the current fiscal year.

Institutional Investors Weigh In On Bio-Rad Laboratories

Large investors have recently added to or reduced their stakes in the stock. Quent Capital LLC bought a new position in shares of Bio-Rad Laboratories in the third quarter worth $25,000. Danske Bank A S bought a new position in shares of Bio-Rad Laboratories in the fourth quarter worth $30,000. Hollencrest Capital Management bought a new position in shares of Bio-Rad Laboratories in the first quarter worth $28,000. Geneos Wealth Management Inc. grew its stake in shares of Bio-Rad Laboratories by 115.2% in the second quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock worth $34,000 after purchasing an additional 76 shares in the last quarter. Finally, Los Angeles Capital Management LLC bought a new position in shares of Bio-Rad Laboratories in the fourth quarter worth $47,000. 65.24% of the stock is owned by institutional investors and hedge funds.

Bio-Rad Laboratories Company Profile

(Get Free Report)

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.